ABSTRACT
Introduction Few biomarkers can be clinically used to diagnose and assess the severity of depression. However, a decrease in activity and sleep efficiency can be observed in depressed patients, and recent technological developments have made it possible to measure these changes. In addition, physiological changes, such as heart rate variability, can be used to distinguish depressed patients from normal persons; these parameters can be used to improve diagnostic accuracy. The proposed research will explore and construct machine learning models capable of detecting depressive episodes and assessing their severity using data collected from wristband-type wearable devices.
Methods Patients with depressive symptoms and healthy subjects will wear a wristband-type wearable device for 7 days; data on triaxial acceleration, pulse rate, skin temperature, and ultraviolet light will be collected. On the seventh day of wearing, the severity of depressive episodes will be assessed using SCID-5, HAMD, and other scales. Data for up to five 7-day periods of device wearing will be collected from each subject. Using wearable device data associated with clinical symptoms as supervisory data, we will explore and build a machine learning model capable of identifying the presence or absence of depressive episodes and predicting the HAMD scores for an unknown data set.
Discussion Our machine learning model could improve the clinical diagnosis and management of depression through the use of a wearable medical device.
Trial Registration jRCT1031210478, Japan Registry of Clinical Trials (jRCT)
Competing Interest Statement
The author(s) declare the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: T. Kishimoto is the president of i2medical LLC and has received consultant fees from Otsuka, Pfizer, and Sumitomo and speaking fee from Banyu, Eli Lilly, Sumitomo, Janssen, Novartis, Otsuka, and Pfizer. T. Horigome is a board member of i2medical LLC and had received consulting fees from FRONTEO Inc. Y. Tazawa is a board member of i2medical LLC. K.C. Liang is a board member of i2medical LLC. N. Koga is a board member of i2medical LLC. G. Miura has received speaking fees from Janssen, Meiji Seika Pharma, Otsuka, and Yoshitomi Yakuhin. The authors have no other conflicts of interest to declare.
Clinical Trial
jRCT1031210478
Funding Statement
This research is supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number 21uk1024003h0001.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Keio University School of Medicine Ethics Committee gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Not applicable.
